ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CTOR vs NMAD // OPERATING MARGIN

Citius Oncology Inc. (NASDAQ) VS. Nomad Power Solutions Inc. (NASDAQ) • 15-METRIC TALLY: CTOR 0 — NMAD 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTOR VS. NMAD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CTOR NMAD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -11.16% -5.39% -5.77 NMAD /fcf-yield <GO>
Operating Margin ACTIVE — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 NMAD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.1 41.0 -3.90 NMAD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $55.2M $55.9M -$630.6K NMAD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CTOR REV NMAD REV CTOR GROSS % NMAD GROSS % CTOR FCF NMAD FCF
FY 2025 $65.9M $14.3M — — -$5.5M -$3.1M
FY 2024 $57.6M $10.0M — — $126.4K -$3.2M
FY 2023 $2.8M $14.3M — — -$601.3K -$4.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTOR // BETA —
NMAD // BETA —